Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1646 - FPR as a prognostic biomarker in stage II and III gastric cancer (52P)


18 Nov 2017


Poster lunch


Translational Research;  Gastric Cancer


Jing Zhang


Annals of Oncology (2017) 28 (suppl_10): x7-x15. 10.1093/annonc/mdx653


J. Zhang, X. Wang, H. Ying

Author affiliations

  • Department Of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University, 330006 - nanchang/CN


Abstract 1646


Inflammation and nutrition are two main causes contributing to progression of gastric cancer (GC), and inflammatory biomarker may be presented as its valuable prognostic factor. Thus, this study was carried out to investigate the prognostic significance of preoperative circulating albumin/fibrinogen ratio (AFR), fibrinogen/pre-Albumin ratio (FPR), fibrinogen (Fib), albumin (Alb) and pre-Albumin (pAlb) in surgical GC.


Materials and Methods: Three hundred and sixty surgical stage II and III GC patients from June 2011 to December 2013 were enrolled in this retrospective study. X-tile software, Kaplan-Meier curve and Cox regression model were used to evaluate the prognostic role of them. A predictive nomogram was established to predict prognosis of overall survival (OS), and its accuracy was assessed by concordance index (c-index).


Decreased Alb (adjusted HR = 1.614, 95%CI=1.103-2.361), pAlb (adjusted HR = 2.111, 95%CI=1.437-3.100), AFR (adjusted HR = 1.540, 95%CI=1.013-2.343) and elevated FPR (adjusted HR = 2.325, 95%CI=1.372-3.940) were significantly associated with shorter OS. FPR was identified as the most effective prognostic factor to predict 3-year’s OS by identified as the most effective prognostic factor to predict 3-year’s OS by time-dependent ROC analysis. A long survival was observed in stage II (P = 0.007) and III (P = 0.002) GC patients with low level of FPR comparing to the patients with high FPR, and the prognosis of III stage FPR-low GC patients undergoing adjuvant chemotherapy was significantly superior to the patients without the treatment (P = 0.002). However, no difference of survival was examined in II stage subgroups stratified by FPR and high FRP of III stage patients with or not the treatment of adjuvant chemotherapy. C-index of nomogram containing FPR (c-index=0.756) was high in comparison with the nomogram without FPR (c-index =0.748).


Preoperative FPR might be a feasible prognostic biomarker in surgical stage II and III GC patients and it could precisely distinguish stage III patients who appeared to benefit from adjuvant chemotherapy. Meanwhile established nomogram based on clinical parameters and FPR could improve its predictive efficacy in 3 years’ OS.

Clinical trial identification

Legal entity responsible for the study

The study was approved by the Ethical Committee of the Second Affiliated Hospital of Nanchang University.




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.